BioPharmSignal logoBioPharmSignal

Biotech News

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Design Therapeutics (DSGN)Design TherapeuticsEarnings

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at

Related news

DSGNDesign Therapeutics2025-08-07 20:01 EST

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

DSGNDesign Therapeutics2026-04-28 20:01 EST

Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

View all latest news

Design Therapeutics

GeneTAC Platform Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene. DT-216P2 DT-216P2 is being developed for Friedreich ataxia and is designed to increase...

Recent company news

DSGNDesign Therapeutics2026-08-03 12:00 EST

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

DSGNDesign Therapeutics2026-06-30 12:00 EST

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

DSGNDesign Therapeutics2026-05-28 12:00 EST

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

DSGNDesign Therapeutics2026-05-18 11:00 EST

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DSGNDesign Therapeutics2026-05-17 20:00 EST

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Stock data

Close
14.99 USD
Market cap
635.19M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States